RxDoctor Payments Data

Kevin Varden, MD

Internal Medicine · Mobile, ALNPI 1417903113

Payments from drug & device makers

$16,403in general payments, 2019–2025

Across 1,353 payments — averaging $12.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Amgen$1K
  • GSK$998
  • Pfizer$942
  • Johnson & Johnson$940
  • plus $7K from 49 others

What the payments were for

  • Food & beverage$16,27499%
  • Education$1281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,403 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$443,039
Medicare patients
1,038
Services billed
16,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide329$338,322
EliquisApixaban419$275,784
FarxigaDapagliflozin Propanediol185$156,051
MounjaroTirzepatide113$130,801
JardianceEmpagliflozin144$121,996
MyrbetriqMirabegron161$99,606
TrulicityDulaglutide74$85,330
LinzessLinaclotide95$85,096
XareltoRivaroxaban72$68,301
RybelsusSemaglutide48$65,370
JanuviaSitagliptin Phosphate62$56,955
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$56,232
VraylarCariprazine Hcl21$44,832
Breo ElliptaFluticasone/Vilanterol89$35,105
TradjentaLinagliptin81$33,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,012$403,692377 claims
PfizerEliquis$942$275,784419 claims
Lilly USA, LLCMounjaro, Trulicity$681$216,131187 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$617$185,106224 claims
Boehringer IngelheimJardiance, Tradjenta$578$155,539225 claims
AbbVieLinzess, Vraylar, Synthroid$2,904$139,183243 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$998$120,743214 claims
Astellas Pharma US IncMyrbetriq$370$99,606161 claims
Johnson & JohnsonXarelto$940$68,30172 claims
MerckJanuvia$342$56,95562 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$146$24,87530 claims
NovartisEntresto$744$21,48527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →